

REPORT ID
LD-ESQUSAMPLE RECEIVED
02 OCTOBER 2026DATE TESTED
06 OCTOBER 2026

01 / SAMPLE DETAILS

Tirzepatide

Lyophilized Powder (Vial)


Client

Company Enhanced Research Compounds

Origin Enhanced Research Compounds

Batch Not stated

Label claim 10 mg



VIAL AS RECEIVED

LD-ESQU

TESTS REQUESTED

Identity (LC-MS), purity (HPLC) and content (HPLC) of a peptide vial or vials.

02 / RESULTS

CONTENT (HPLC)

9.21 mg

92.1% of claim

PURITY (HPLC)

99.57%

IDENTITY (LC-MS)

Confirmed

DETAILED FINDINGS

Label claim	10 mg
Content (HPLC)	9.21 mg (92.1%)
Purity (HPLC)	99.57%
Identity (LC-MS)	Confirmed

OVERALL ASSESSMENT

Pass

03 / ANALYSIS & VERIFICATION



Analysis by Samir Dhakal, Apex Labs

Analysis conducted: 06 OCTOBER 2026

Report Compiled by Lab Doc Aus Pty Ltd, 07 OCTOBER 2026

This report covers the tested sample only. LabDoc does not sell, supply or endorse any product or supplier, and this report is not a statement that any product is lawful, safe or suitable for use.

